therapeutic strategies for myelofibrosis are evolving, with emerging approaches being explored to address various aspects of the disease, including associated anemia. some of these strategies may involve the use of jak inhibitors, although challenges and gaps in guidance remain. the broader context of these developments is part of a larger landscape of advances in cancer treatment, with research also focusing on other types of blood cancers and related conditions.